Microbiome Therapeutics: Global Markets

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,500	175 Pages	BCC Research	January, 2023	WA17692855

Best Price Guarantee
Price	from $5,500
Length	175 Pages
Publisher	BCC Research
Published Date	January, 2023
SKU	WA17692855

Companies Mentioned

4d Pharma
Ao Biome Llc
Armata Pharmaceuticals
Assembly Biosciences Inc.
Azitra Inc.
Biomica
Biomx
Chain Biotechnology Ltd.
Eligo Bioscience Sas
Enterome Sa
Evelo Biosciences
Finch Therapeutics Group Inc.
Intralytix Inc.
Maat Pharma
Osel Inc.
Pylum Biosciences Inc.
Quorum Innovations Llc
Rebiotix Inc. (A Ferring Company)
Second Genome
Senda Biosciences Inc.
Seres Therapeutics Inc.
Sfa Therapeutics Inc.
Synlogic
Theriva Biologics Inc.
Vedanta Biosciences Inc.
Ysopia Bioscience Inc.Report Scope:

BCC Research’s new report, Microbiome Therapeutics: Global Markets, provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2027. The report analyzes the market by segmenting it into the various types of microbiome therapeutics, based on the strategies used for treatment: additive (fecal matter transplants or FMTs, live biotherapeutic products or LBPs), modulatory (postbiotics, prebiotics) and subtractive microbiome therapeutics (phages and antimicrobials). This study surveys the microbiome therapeutics market by application or disease segment: infectious diseases, metabolic diseases, cancer, gut-brain axis, and others. The market is assessed in the following geographic regions: North America, Europe, and emerging markets. Emerging markets include countries like India, China, Korea, Taiwan, Africa, Australia, New Zealand, Canada, and Latin America.

The report features leading clinical trials indicating the status and phase of development. New developments and patents are boosting growth of this market in the global context.

The new BCC report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on the changing market trends, market players and leading pipeline candidates. This chapter covers influential mergers and acquisitions and other collaborations or partnerships that happened during the evaluation period of this report.

Strengths, weaknesses, threats, and opportunities that are expected to play a role in the microbiome therapeutics market are evaluated in detail.

The markets for prebiotics and probiotics labeled as nutritional or dietary supplements are excluded from this report. Prebiotics and probiotics are included when used in the context of microbiome therapy.

Report Includes:

32 data tables and 44 additional tables

An up-to-date overview and analysis of the global and regional markets for microbiome therapeutics

Analyses of the global market trends, with historic market revenue (sales data) for 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2027

Discussion of the industry growth driving factors and major technology challenges and issues affecting the market for microbiome therapeutics as a basis for projecting demand over the next few years (2022-2027)

Estimation of the actual market size and revenue forecast for global microbiome therapeutics market in USD million terms, and corresponding market share analysis by technology type, application, and region

Highlights of this innovation driven market covering current trends in genome sequencing industry, disease areas of application, clinical trials and their stages, and recent breakthrough innovations etc.

Assessment of the recent industry structure for microbiome therapeutics, ongoing research (R&D) activities, analysis of competitive environment, and the COVID-19 impact on the marketplace

Review of the patents and patent applications on microbiome therapeutics, and related scientific publications during the analysis period

Competitive landscape of this market featuring leading biopharmaceutical companies, their product portfolios, financial updates, and market share analysis based on recent segmental revenues

Profile description of the major market participants, including Assembly Biosciences, Finch Therapeutics, Second Genome, Evelo Biosciences, Ysopia Bioscience and Evelo Biosciences4D PHARMA AO BIOME LLC ARMATA PHARMACEUTICALS ASSEMBLY BIOSCIENCES INC. AZITRA INC. BIOMICA BIOMX CHAIN BIOTECHNOLOGY LTD. ELIGO BIOSCIENCE SAS ENTEROME SA EVELO BIOSCIENCES FINCH THERAPEUTICS GROUP INC. INTRALYTIX INC. MAAT PHARMA OSEL INC. Pylum Biosciences Inc. QUORUM INNOVATIONS LLC Rebiotix Inc. (a Ferring Company) SECOND GENOME Senda biosciences INC. SERES THERAPEUTICS INC. SFA THERAPEUTICS INC. SYNLOGIC THERIVA Biologics Inc. VEDANTA BIOSCIENCES INC. YSOpia bioscience Inc.

Chapter 1 Introduction: 1.1 Study Goals and Objectives; 1.2 Reasons for Doing This Study; 1.3 What's New in This Report?; 1.4 Scope of Report; 1.5 Information Sources; 1.6 Methodology; 1.7 Geographic Breakdown; 1.8 Analyst's Credentials; 1.9 BCC Custom Research; 1.10 Related BCC Research Reports
Chapter 2 Summary and Highlights: 2.1 Key Highlights
Chapter 3 Market and Technology Background: 3.1 Benefits; 3.2 The Human Microbiome; 3.2.1 Different Microbiomes in Humans; 3.2.2 Microbiome, Human Health and Disease; 3.2.3 Technologies Aiding Microbiome Research; 3.2.4 Microbiome Research Projects; 3.3 Microbiome Therapeutics; 3.3.1 Strategies for the Development of Microbiome Therapeutics; 3.3.2 Microbiome Therapeutics Disease Areas; 3.3.3 Regulatory Landscape for Microbiome Therapeutics
Chapter 4 Market Breakdown by Type of Therapeutic: 4.1 Introduction; 4.2 Market Overview; 4.2.1 Market Revenue; 4.2.2 Market Shares; 4.3 Additive Microbiome Therapeutics; 4.3.1 Fecal Microbiota Transplants (FMTs); 4.3.2 Live Biotherapeutic Products (LBPs); 4.3.3 Market Overview; 4.3.4 Market Revenue; 4.3.5 Market Shares; 4.4 Modulatory Microbiome Therapeutics; 4.4.1 Mechanism of Action; 4.4.2 Current Status; 4.4.3 Market Overview; 4.4.4 Market Revenue; 4.4.5 Market Shares; 4.5 Subtractive Microbiome Therapeutics; 4.5.1 Mechanism of Action; 4.5.2 Current Status; 4.5.3 Market Overview; 4.5.4 Market Revenue; 4.5.5 Market Shares
Chapter 5 Market Breakdown by Application: 5.1 Introduction; 5.1.1 Market Revenue; 5.1.2 Market Shares; 5.2 Infections; 5.2.1 Clostridium Difficile Infection (CDI); 5.2.2 Urinary Tract Infection (UTI); 5.2.3 COVID-19; 5.2.4 Market Overview; 5.2.5 Market Revenue; 5.3 Gastrointestinal (GIT) Diseases; 5.3.1 Market Overview; 5.3.2 Market Revenue; 5.4 Metabolic Diseases; 5.4.1 Market Overview; 5.4.2 Market Revenue; 5.5 Cancer; 5.5.1 Market Overview; 5.5.2 Market Revenue; 5.6 Gut-Brain Axis Diseases; 5.6.1 Market Overview; 5.6.2 Market Revenue; 5.7 Other Diseases; 5.7.1 Market Overview; 5.7.2 Market Revenue; 5.8 Regional Markets Globally; 5.8.1 Market Shares
Chapter 6 Industry Structure: 6.1 Investment in Microbiome Therapeutics; 6.1.1 Public Funding Initiatives; 6.1.2 Private Funding Initiatives; 6.2 Collaborations and Partnerships; 6.3 Licensing and Manufacturing Agreements; 6.4 Mergers and Acquisitions; 6.5 Leading Market Players in the Market for Microbiome Therapeutics; 6.5.1 Leading Market Players in Market for Additive Microbiome Therapeutics; 6.5.2 Leading Market Players in the Market for Modulatory Microbiome Therapeutics; 6.5.3 Leading Market Players in the Market for Subtractive Microbiome Therapeutics; 6.6 BCC Research Select Insights from Industry Leaders
Chapter 7 Patent Analysis: 7.1 Patent Analysis; 7.1.1 Patents by Year; 7.1.2 Patents by Type; 7.1.3 Patents by Type of Disease; 7.1.4 Patents by Company; 7.1.5 Patents by Country; 7.1.6 Patents by Assignee
Chapter 8 Clinical Trials: 8.1 Clinical Trials by Disease Category; 8.1.1 Distribution Shares of Clinical Trials; 8.2 Clinical Trials by Type of Therapeutic; 8.2.1 Distribution Shares of Clinical Trials by Type of Therapeutic; 8.3 Clinical Trials by Company; 8.3.1 Distribution Shares of Clinical Trials by Company; 8.3.2 Microbiome Therapeutics in Discovery and Preclinical Development; 8.3.3 Microbiome Therapeutics in Phase 3 Clinical Trials
Chapter 9 Analysis of Market Opportunities: 9.1 SWOT Analysis; 9.1.1 Strengths of Market for Microbiome Therapeutics; 9.1.2 Challenges in the Market for Microbiome Therapeutics; 9.1.3 Opportunities in the Market for Microbiome Therapeutics; 9.1.4 Threats to the Market for Microbiome Therapeutics
Chapter 10 Company Profiles: 4D PHARMA; AO BIOME LLC; ASSEMBLY BIOSCIENCES INC.; ARMATA PHARMACEUTICALS; AZITRA INC.; BIOMICA; BIOMX; CHAIN BIOTECHNOLOGY LTD.; ELIGO BIOSCIENCE SAS; ENTEROME SA; EVELO BIOSCIENCES; FINCH THERAPEUTICS GROUP INC.; INTRALYTIX INC.; MAAT PHARMA; OSEL INC.; PYLUM BIOSCIENCES INC.; QUORUM INNOVATIONS LLC; REBIOTIX INC. (A FERRING COMPANY); SECOND GENOME; SENDA BIOSCIENCES INC.; SERES THERAPEUTICS INC.; SFA THERAPEUTICS INC.; SYNLOGIC; THERIVA BIOLOGICS INC.; VEDANTA BIOSCIENCES INC.; YSOPIA BIOSCIENCE INC.
Chapter 11 Appendix: Acronyms